Structured evidence table for Fucoxanthin Metabolic Wellness Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Fucoxanthin Metabolic Wellness Randomized Trial | In obesity, an imbalance in gut microbial composition (dysbiosis) is frequently observed, with reduced microbial diversity and a higher ratio of Firmicutes to Bacteroidetes phyla in some studies []. | 3 | Limijadi Edward Kurnia Setiawan (2025) | Marine-Algal-Derived Postbiotics Modulating the Gut Microbiota–Adipose Tissue Axis in Obesity: A New Frontier |
| Fucoxanthin Metabolic Wellness Randomized Trial | This dysbiotic state can promote greater energy harvest from diet and increased intestinal permeability, leading to elevated circulating endotoxin (lipopolysaccharide, LPS) levels that trigger inflammation in adipose tissue []. | 3 | Limijadi Edward Kurnia Setiawan (2025) | Marine-Algal-Derived Postbiotics Modulating the Gut Microbiota–Adipose Tissue Axis in Obesity: A New Frontier |
| Fucoxanthin Metabolic Wellness Randomized Trial | We then delve into the diverse types of marine algae (brown, red, green macroalgae, and microalgae) and their key bioactive components, summarizing evidence from animal models and human trials on their anti-obesity effects via gut microbiota modulation. | 3 | Limijadi Edward Kurnia Setiawan (2025) | Marine-Algal-Derived Postbiotics Modulating the Gut Microbiota–Adipose Tissue Axis in Obesity: A New Frontier |
| Fucoxanthin Metabolic Wellness Randomized Trial | 1 2 3 3 4 5 3 Obesity is a multifactorial metabolic disorder characterized by excess adipose tissue and chronic low-grade inflammation []. | 3 | Limijadi Edward Kurnia Setiawan (2025) | Marine-Algal-Derived Postbiotics Modulating the Gut Microbiota–Adipose Tissue Axis in Obesity: A New Frontier |
Source documents